Applying this HBB gene correction process to SCD patient-HSPCs results in over 50% expression of normal adult hemoglobin in mature red blood cells and in the correction of sickle phenotype, without inducing βthalassemic phenotype. Edited HSPCs engraft efficiently in an immunodeficient murine model and maintain clinically relevant levels of HBB gene correction events. This comprehensive preclinical data package sets the stage for the therapeutic application of autologous gene corrected HSPCs to address SCD. ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Cellectis leverages TALEN® technology and a non-viral gene repair template delivery to develop a clinically relevant gen ...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its product candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL). UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in ...

Financial Data and Key Metrics Changes - The consolidated net income attributable to shareholders of Cellectis was $5.6 million or $0.08 income per share for the three months ended March 31, 2024, compared to a $30.1 million loss or a $0.58 loss per share for the same period in 2023 [32] - The consolidated adjusted net income attributable to shareholders was $6.5 million or $0.09 income per share for Q1 2024, compared to a net loss of $28.1 million or $0.55 loss per share for Q1 2023 [34] - Cash, cash equivalents, restricted cash, and fixed-term deposits classified as current financial assets as of March 31, 2024, amounted to $143 million, down from $156 million as of December 31, 2023 [22] Business Line Data and Key Metrics Changes - Cellectis continues to focus on advancing its core clinical trials: BALLI-01, NatHaLi-01, and AMELI-01, while also building the next generation of genomic medicine [6] - The BALLI-01 trial showed a higher preliminary response rate of 67% at dose Level 2 compared to a 50% response rate at a higher dose Level 3 using UCART22-P1 [18] - The NatHaLi-01 study continues to enroll patients, with initial data supporting the continued study of UCART20x22 in relapsed/refractory B-cell non-Hodgkin lymphoma [20] Market Data and Key Metrics Changes - AstraZeneca's investment increased its ownership to approximately 44% of Cellectis' share capital and 30% of voting rights, indicating strong market confidence [15] - The company expects its cash runway to fund operations into 2026, bolstered by the recent $140 million equity investment from AstraZeneca [24] Company Strategy and Development Direction - Cellectis aims to leverage its collaboration with AstraZeneca to develop up to 10 cell and gene therapy programs across various indications, including oncology and immunology [44] - The company is focused on maintaining an efficient corporate infrastructure to limit growth in general and administrative expenses while advancing its clinical candidates [35] - The strategic collaboration with AstraZeneca is expected to enhance Cellectis' capabilities in manufacturing and research, positioning the company for significant advancements in the cell and gene therapy space [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for a paradigm shift in treating hard-to-treat cancers through their proprietary technologies [27] - The management highlighted the importance of AstraZeneca's long-term vision and investment in the cell and gene therapy space, which aligns with Cellectis' strategic goals [44] - The company is optimistic about the upcoming data disclosures for its clinical trials by the end of 2024, which are expected to provide insights into the efficacy and safety of its therapies [46] Other Important Information - Research costs under the AstraZeneca collaboration are funded by AstraZeneca, allowing Cellectis to focus its resources on developing its clinical candidates [35] - The company has appointed Arthur Stril as interim Chief Financial Officer, following the resignation of Bing Wang, to guide financial strategies during this critical period [103] Q&A Session Summary Question: Any strategic change regarding the strategy from a Cellectis perspective with AstraZeneca on board? - The strategy on wholly owned assets remains unchanged, with continued focus on UCART22, UCART20x22, and UCART123, while also pursuing novel programs with AstraZeneca across various indications [30] Question: Status of enrollment for both BALLI-01 and NatHaLi-01? - Enrollment continues for both studies, with expectations to complete the escalation phase by the end of the year [31] Question: How many sites are active for UCART20x22 and expectations for RP2D by year-end? - Active sites are open in the U.S. and EU, and the company aims to declare RP2D by the end of the year [48] Question: Can you provide any further granularity on the cadence of readouts across the program this year? - The company will disclose data results for both BALLI-01 and NatHaLi-01 later this year, focusing on durability and response rates [62] Question: Will the dose expansion studies convert to registrational studies? - Discussions with regulatory authorities are ongoing regarding the potential for pivotal expansions, with target populations including relapsed/refractory ALL and non-Hodgkin lymphoma [75][76]

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life- sav ...

Core Points - Cellectis, a clinical-stage biotechnology company, is set to hold its annual general meeting on June 28, 2024, at 2:30 p.m. CET in Paris, France [1] - The company specializes in gene-editing technology to develop cell and gene therapies, particularly focusing on CAR-T immunotherapies for oncology [2] - Cellectis employs an allogeneic approach for CAR-T therapies, aiming to create off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has over 24 years of experience in gene editing and utilizes TALEN® technology and PulseAgile electroporation system [2] Company Overview - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, North Carolina [2] - The company is publicly traded on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [2] - Cellectis focuses on addressing unmet medical needs through innovative gene editing solutions [2]

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapie ...

as Exhibit 99.1 | --- | --- | --- | |--------------|---------------------------------------------------------------------------------------------------------|-------| | PART I – | FINANCIAL INFORMATION | 3 | | Item 1. | Interim Condensed Consolidated Financial Statements (Unaudited) | 3 | | Item 2. | Management's Discussion & Analysis of Financial Condition and Results of Operations | 42 | | Item 3. | Quantitative and Qualitative Disclosures About Market Risks | 52 | | Item 4. | Controls and Procedures | 52 ...

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 ...

Core Viewpoint - Cellectis, a clinical-stage biotechnology company, is set to report its financial results for Q1 2024 on May 28, 2024, followed by an investor conference call on May 29, 2024, to discuss the results and business updates [1][2]. Company Overview - Cellectis specializes in developing life-saving cell and gene therapies using its gene-editing platform, focusing on CAR-T immunotherapies for oncology and therapeutic gene editing in hemopoietic stem cells [3]. - The company employs an allogeneic approach for CAR-T therapies, aiming to provide off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [3]. - Cellectis has over 24 years of experience in gene editing and utilizes technologies such as TALEN® and PulseAgile to address unmet medical needs [3]. - The company is headquartered in Paris, France, with additional locations in New York and Raleigh, and is listed on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [3].